Covid 19 Clinical Trials

To date, the effects of SARS-Cov-2 (Covid-19) on the myocardium and the role it plays in the evolution towards an acute myocarditis are badly understood. The current pandemic of this emerging virus is an opportunity to assess the proportion of acute myocarditis attributable to SARS-Cov-2(Covid-19) and to assess the clinical, biological and imaging presentations, by means of a national prospective multicentre hospital registry of cases of acute myocarditis.

NCT04375748 Acute Myocarditis Diagnostic Test: Performing routine care (clinical and paraclinical tests) Diagnostic Test: Examinations for the research:

MeSH:Myocarditis

HPO:Myocarditis

Primary Outcomes

Description: Estimate at hospital discharge, over a period of 6 months, the evolution of the proportion of positive SARS-COV-2 cases among patients hospitalized for acute myocarditis in Intensive Cardiac Care Unit or Intensive Care Unit (polyvalent, surgical or medical), in the 19 hospitals participating in the study.

Measure: Evolution of the proportion of positive SARS-COV-2 cases.

Time: 6 months.

Secondary Outcomes

Description: Describe at the admission and during the treatment ultrasound characteristics of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort; Echocardiographic parameters: Volumes (mm3)

Measure: Ultrasound characteristics.

Time: 1 year

Measure: Ultrasound characteristics.

Time: 1 year

Measure: Ultrasound characteristics.

Time: 1 year

Measure: Ultrasound characteristics.

Time: 1 year

Measure: Ultrasound characteristics.

Time: 1 year

Measure: Ultrasound characteristics.

Time: 1 year

Measure: Ultrasound characteristics.

Time: 1 year

Measure: Ultrasound characteristics.

Time: 1 year

Description: Assess the short-term (30 days) and long-term (1 year) prognosis of the acute myocarditis among the positive and negative SARS-Cov-2 patients of the myocarditis cohort. The 30-day prognosis will be defined in function to the outcome: A death, whatever the cause, A cardiovascular arrest with recovery, A cardiogenic shock, An acute lung oedema or One of the events cited above. The 1-year prognosis will be defined in function to the outcome: A death, whatever the cause, The need to resort to transplantation and/or chronic assistance, A rehospitalization for cardiovascular reasons (heart failure, painful relapse, recovered cardiac arrest, myocarditis relapse, ACS), A myocarditis relapse, or one of the events cited above. The 1-year prognosis will also be defined in function to the New York Heart Association (NYHA) class.

Measure: Assess prognosis of the acute myocarditis .

Time: The short-term (30 days) and long-term (1 year).

Description: Identify the factors associated with a 30-day and 1-year prognosis of cases of acute myocarditis cardiovascular (Terminal heart failure, Acute edema of the lung, Cardiogenic shock, Sudden death / Ventricular rhythm disorder Pulmonary embolism, Aortic dissection Infectious endocarditis Stroke) or no cardiovascular (Acute respiratory syndrome, septic shock of non-cardiac origin, cancer, Public road accident, end-stage respiratory failure, insufficiency, end-stage renal Failure)

Measure: The factors associated with acute myocarditis cases .

Time: The short-term (30 days) and long-term (1 year).

Description: Describe the biological parameters on admission and during the treatment (troponinemia (ng/ml)

Measure: Biological characteristics

Time: 1 year

Description: Describe the biological parameters on admission and during the treatment NtproBNP(pg/ml)

Measure: Biological characteristics

Time: 1 year

Description: Describe the biological parameters on admission and during the treatment CRP(mg/ml)

Measure: Biological characteristics

Time: 1 year

Description: Ventricular volumes (ml)